Invasive fungal infection: Difference between revisions

From IDWiki
(→: updated probable infection to 2019 guidelines)
m (→)
 
(12 intermediate revisions by the same user not shown)
Line 1: Line 1:
== Microbiology ==
==Background==
===Microbiology===


*Molds
* Endemic fungi
** [[Histoplasmosis]]
**[[Aspergillus]]
** [[Blastomycosis]]
**[[Zygomycosis]]
** [[Coccidioidomycosis]]
**[[Fusarium]]
** [[Paracoccidioidomycosis]]
**[[Scedosporium]]
*Yeasts
** [[Sporotrichosis]]
**[[Candida]]
** ''[[Penicillium marneffei]]''
**[[Cryptococcus]]
* Other fungi
**Excludes [[Pneumocystis]]
** Molds
*Endemic fungi
*** [[Aspergillus species]]
*** [[Zygomycosis]]
**[[Histoplasmosis]]
*** [[Fusarium]]
**[[Blastomycosis]]
*** [[Scedosporium]]
**[[Coccidioidomycosis]]
**[[Paracoccidioidomycosis]]
** Yeasts
*** [[Candida]]
**[[Sporotrichosis]]
**''[[Penicillium marneffei]]''
*** [[Cryptococcus]]
* Excludes [[Pneumocystis]]


== Epidemiology ==
===Epidemiology===


* Among patients on posaconazole for a hematologic malignancy or bone marrow transplant, there is an approximately 2% rate of breakthrough infection [[CiteRef::cornely2007po]]
*Among patients on posaconazole for a hematologic malignancy or bone marrow transplant, there is an approximately 2% rate of breakthrough infection [[CiteRef::cornely2007po]]


== Classification (excluding endemic fungi) ==
==Classification==
=== Probable invasive pulmonary mold disease ===
* The classification for probable invasive pulmonary mold disease requires at least one patient risk factor (host factor), one clinical criterion (e.g. imaging), and one mycological criterion [[CiteRef:: donnelly2019re]]
* '''Host factors'''
** Recent history of '''neutropenia''' (<0.5 × 109 neutrophils/L for >10 days) temporally related to the onset of fungal disease
** '''Hematologic malignancy''' (active, in treatment, or recent)
** Receipt of an '''allogeneic stem cell transplant'''
** Prolonged use of '''corticosteroids''' (excluding [[ABPA]]) at a mean minimum dose of 0.3 mg/kg/day of [[prednisone]] equivalent for ≥3 weeks in the past 60 days
** Treatment with other recognized '''T-cell immunosuppressants''', such as calcineurin inhibitors, TNF-α inhibitors, specific monoclonal antibodies (such as [[alemtuzumab]]), or nucleoside analogues during the past 90 days
** Treatment with certain '''B-cell immunosuppressants''', including [[ibrutinib]]
** '''Inherited severe immunodeficiency''', such as [[chronic granulomatous disease]], [[STAT 3 deficiency]], or [[severe combined immunodeficiency]]
** Acute '''graft-versus-host disease''' grade III or IV, involving gut, lungs, or liver, which is refractory to first-line steroids
* '''Clinical criteria'''
** '''Pulmonary aspergillosis''': any of the following patterns on CT
*** Dense, well-circumscribed lesions with or without a halo sign
*** Air crescent sign
*** Cavity
*** Wedge-shaped and segmental or lobar consolidation
** '''Other pulmonary mold disease''': as above, but also including a reverse halo sign
** '''Tracheobronchitis''': tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on bronchoscopic analysis
** '''Sinonasal infection''':
*** Acute localized pain (including pain radiating to the eye)
*** Nasal ulcer with black eschar
*** Extension from the paranasal sinus across bony barriers, including into the orbit
** '''CNS infection''': 1 of the following 2 signs
*** Focal lesions on imaging
*** Meningeal enhancement on MRI or CT
* '''Mycological criteria'''
** '''Direct test''' (cytology, direct microscopy, or culture)
*** Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate samples, indicated by 1 of the following:
*** Presence of fungal elements indicating a mold
*** Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or Scedosporium species)
** '''Tracheobronchitis'''
*** [[Aspergillus species]] on BAL or bronchial brush culture
*** Microscopy showing fungal elements on BAL or bronchial brush
** Sinonasal disease
*** Mold on culture or microscopy of sinus aspirate
** For [[Aspergillus species]]
*** Galactomannan in plasma, serum, BAL, or CSF
**** Serum or plasma ≥1
**** BAL ≥1
**** Serum or plasma ≥0.7 and BAL ≥0.8
**** CSF ≥1
*** PCR
**** Plasma, serum, or whole blood positive on 2 consecutive tests
**** BAL positive on 2 or more tests
**** At least 1 positive from plasma, serum, or whole blood and one positive from BAL


*The classification for invasive fungal infections requires a combination of host factors (i.e. strong risk factor), clinical criteria (e.g. imaging), and mycological criteria (e.g. culture or serology)[[CiteRef:: donnelly2019re]]
=== Proven ===
*It excludes endemic fungi
* Fungal elements in biopsy of diseased tissue, or highly specific indirect assays
* Includes:
** [[Aspergillus]] in culture
** [[Histoplasma capsulatum]]: intracellular budding yeasts
** [[Coccidioides species]]: spherules
** [[Paracoccidioides brasiliensis]]: large yeasts with multiple daughter yeasts in a “pilot-wheel configuration”
** [[Blastomyces dermatitidis]]: thick-walled, broad-based budding yeasts
* Can include [[Coccidioides]] antibodies in CSF, or [[Cryptococcus]] capsular antigen in CSF
* Does ''not'' include urine antigens


=== Probable ===
===Invasive Pulmonary Mold Disease===


*Interpretation
* Requires a susceptible host, clinical/radiographic features, and mycological evidence
**'''Possible''' IFD requires a host factor and a clinical feature, without mycological evidence
**'''Probable''' IFD requires the presence of at least 1 host factor, a clinical feature, and mycologic evidence, and is relevant for immunocompromised patients only
**'''Proven''' IFD is based on histopathology and can apply to any patient, regardless of whether the patient is immunocompromised
*'''Host factors'''
**Recent history of '''neutropenia''' (<0.5 × 109 neutrophils/L for >10 days) temporally related to the onset of fungal disease
**'''Hematologic malignancy''' (active, in treatment, or recent)
**Receipt of an '''allogeneic stem cell transplant'''
**Prolonged use of '''corticosteroids''' (excluding [[ABPA]]) at a mean minimum dose of 0.3 mg/kg/day of [[prednisone]] equivalent for ≥3 weeks in the past 60 days
**Treatment with other recognized '''T-cell immunosuppressants''', such as calcineurin inhibitors, TNF-α inhibitors, specific monoclonal antibodies (such as [[alemtuzumab]]), or nucleoside analogues during the past 90 days
**Treatment with certain '''B-cell immunosuppressants''', including [[ibrutinib]]
**'''Inherited severe immunodeficiency''', such as [[chronic granulomatous disease]], [[STAT 3 deficiency]], or [[severe combined immunodeficiency]]
**Acute '''graft-versus-host disease''' grade III or IV, involving gut, lungs, or liver, which is refractory to first-line steroids
*'''Clinical features'''
**'''[[Pulmonary aspergillosis]]''': any of the following patterns on CT
***Dense, well-circumscribed lesions with or without a halo sign
***Air crescent sign
***Cavity
***Wedge-shaped and segmental or lobar consolidation
**'''Other pulmonary mold disease''': as above, but also including a reverse halo sign
**'''Tracheobronchitis''': tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on bronchoscopic analysis
**'''Sinonasal infection''':
***Acute localized pain (including pain radiating to the eye)
***Nasal ulcer with black eschar
***Extension from the paranasal sinus across bony barriers, including into the orbit
**'''CNS infection''': 1 of the following 2 signs
***Focal lesions on imaging
***Meningeal enhancement on MRI or CT
*'''Mycological evidence'''
**'''Direct test''' (cytology, direct microscopy, or culture)
***Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate samples, indicated by 1 of the following:
***Presence of fungal elements indicating a mold
***Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or Scedosporium species)
**'''Tracheobronchitis'''
***[[Aspergillus]] on BAL or bronchial brush culture
***Microscopy showing fungal elements on BAL or bronchial brush
**Sinonasal disease
***Mold on culture or microscopy of sinus aspirate
**For [[Aspergillus]]
***[[Galactomannan]] in plasma, serum, BAL, or CSF
****Serum or plasma ≥1
****BAL ≥1
****Serum or plasma ≥0.7 and BAL ≥0.8
****CSF ≥1
***PCR
****Plasma, serum, or whole blood positive on 2 consecutive tests
****BAL positive on 2 or more tests
****At least 1 positive from plasma, serum, or whole blood and one positive from BAL


=== Possible ===
===Other Invasive Fungi===
====[[Candidiasis]]====


*'''Host factors'''
* Only cases with the appropriate host factors and with sufficient clinical/radiographic evidence ''without'' supporting mycological evidence
**Recent history of neutropenia <0.5 × 109 neutrophils/L (<500 neutrophils/mm3 for >10 days) temporally related to the onset of invasive fungal disease
* Not used for endemic fungi
**Hematologic malignancy
**Receipt of an allogeneic stem cell transplant
**Solid organ transplant recipient
**Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a therapeutic dose of ≥0.3 mg/kg corticosteroids for ≥3 weeks in the past 60 days
**Treatment with other recognized T-cell immunosuppressants, such as calcineurin inhibitors, tumor necrosis factor-a blockers, lymphocyte-specific monoclonal antibodies, immunosuppressive nucleoside analogues during the past 90 days
**Inherited severe immunodeficiency (such as chronic granulomatous disease, STAT 3 deficiency, CARD9 deficiency, STAT-1 gain of function, or severe combined immunodeficiency)
**Acute graft-versus-host disease grade III or IV involving the gut, lungs, or liver that is refractory to first-line treatment with steroids
*'''Clinical features'''
**At least 1 of the following 2 entities after an episode of candidemia within the previous 2 weeks:
***Small, target-like abscesses in liver or spleen (bull’s-eye lesions) or in the brain, or, meningeal enhancement
***Progressive retinal exudates or vitreal opacities on ophthalmologic examination
*'''Mycological evidence'''
**ß-D-glucan (Fungitell) ≥80 ng/L (pg/mL) detected in at least 2 consecutive serum samples provided that other etiologies have been excluded
**Positive T2Candida

====[[Cryptococcosis]]====

*'''Host factors'''
**HIV infection
**Solid organ or stem cell transplant recipient
**Hematologic malignancy
**Antibody deficiency (eg, common variable immunoglobulin deficiency)
**Immunosuppressive therapy (including monoclonal antibodies)
**End-stage liver or renal disease
**Idiopathic CD4 lymphocytopenia
*'''Clinical features'''
**Meningeal inflammation
**Radiological lesion consistent with cryptococcal disease
*'''Mycological evidence'''
**Recovery of Cryptococcus from a specimen obtained from any nonsterile site

====[[Pneumocystosis]]====

*'''Host factors'''
**Low CD4 lymphocyte counts <200 cells/mm3 (200 × 106 cells/L) for any reason
**Exposure to medication (antineoplastic therapy, antiinflammatory, or immunosuppressive treatment) associated with T-cell dysfunction
**Use of therapeutic doses of ≥0.3 mg/kg prednisone equivalent for ≥2 weeks in the past 60 days
**Solid organ transplant
*'''Clinical features'''
**Any consistent radiographic features particularly bilateral ground glass opacities, consolidations, small nodules or unilateral infiltrates lobar infiltrate, nodular infiltrate with or without cavitation, multifocal infiltrates, miliary pattern
**Respiratory symptoms with cough, dyspnea, and hypoxemia accompanying radiographic abnormalities including consolidations, small nodules, unilateral infiltrates, pleural effusions, or cystic lesions on chest X-ray or computed tomography scan
*'''Mycological evidence'''
**ß-D-glucan (Fungitell) ≥80 ng/L (pg/mL) detection in ≥2 consecutive serum samples provided other etiologies have been excluded
**Detection of Pneumocystis jirovecii DNA by quantitative real-time polymerase chain reaction in a respiratory tract specimen

====[[Endemic mycoses|Endemic Mycoses]]====

*'''Host factors'''
**Not applicable as these diseases affect both healthy and less healthy hosts
*'''Clinical features'''
**Evidence for geographical or occupational exposure (including remote) to the fungus and compatible clinical illness
*'''Mycological evidence'''
**Histoplasma or Blastomyces antigen in urine, serum, or body fluid
**Antibody to Coccidioides in cerebrospinal fluid or 2-fold rise in 2 consecutive serum samples

===Categories===
====Proven====

*Fungal elements in biopsy of diseased tissue, or highly specific indirect assays
*Includes:
**[[Aspergillus]] in culture
**[[Histoplasma capsulatum]]: intracellular budding yeasts
**[[Coccidioides]]: spherules
**[[Paracoccidioides brasiliensis]]: large yeasts with multiple daughter yeasts in a “pilot-wheel configuration”
**[[Blastomyces dermatitidis]]: thick-walled, broad-based budding yeasts
*Can include [[Coccidioides]] antibodies in CSF, or [[Cryptococcus]] capsular antigen in CSF
*Does ''not'' include urine antigens

====Probable====

*Probable invasive fungal diseases requires at least one host factor, a clinical feature, and mycologic evidence
*Only relevant for immunocompromised patients

====Possible====

*Only cases with at least one host factor and at least one clinical evidence, but ''without'' supporting mycological evidence
*Not used for endemic fungi

== Further Reading ==

* Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. ''Clin Infect Dis''. 2020 Sep 12;71(6):1367-1376. doi: [https://doi.org/10.1093/cid/ciz1008 10.1093/cid/ciz1008]. PMID: [https://pubmed.ncbi.nlm.nih.gov/31802125/ 31802125]; PMCID: [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7486838/ PMC7486838].


[[Category:Infectious syndromes]]
[[Category:Infectious syndromes]]

Latest revision as of 21:08, 7 March 2024

Background

Microbiology

Epidemiology

  • Among patients on posaconazole for a hematologic malignancy or bone marrow transplant, there is an approximately 2% rate of breakthrough infection 1

Classification

  • The classification for invasive fungal infections requires a combination of host factors (i.e. strong risk factor), clinical criteria (e.g. imaging), and mycological criteria (e.g. culture or serology)2
  • It excludes endemic fungi

Invasive Pulmonary Mold Disease

  • Interpretation
    • Possible IFD requires a host factor and a clinical feature, without mycological evidence
    • Probable IFD requires the presence of at least 1 host factor, a clinical feature, and mycologic evidence, and is relevant for immunocompromised patients only
    • Proven IFD is based on histopathology and can apply to any patient, regardless of whether the patient is immunocompromised
  • Host factors
    • Recent history of neutropenia (<0.5 × 109 neutrophils/L for >10 days) temporally related to the onset of fungal disease
    • Hematologic malignancy (active, in treatment, or recent)
    • Receipt of an allogeneic stem cell transplant
    • Prolonged use of corticosteroids (excluding ABPA) at a mean minimum dose of 0.3 mg/kg/day of prednisone equivalent for ≥3 weeks in the past 60 days
    • Treatment with other recognized T-cell immunosuppressants, such as calcineurin inhibitors, TNF-α inhibitors, specific monoclonal antibodies (such as alemtuzumab), or nucleoside analogues during the past 90 days
    • Treatment with certain B-cell immunosuppressants, including ibrutinib
    • Inherited severe immunodeficiency, such as chronic granulomatous disease, STAT 3 deficiency, or severe combined immunodeficiency
    • Acute graft-versus-host disease grade III or IV, involving gut, lungs, or liver, which is refractory to first-line steroids
  • Clinical features
    • Pulmonary aspergillosis: any of the following patterns on CT
      • Dense, well-circumscribed lesions with or without a halo sign
      • Air crescent sign
      • Cavity
      • Wedge-shaped and segmental or lobar consolidation
    • Other pulmonary mold disease: as above, but also including a reverse halo sign
    • Tracheobronchitis: tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on bronchoscopic analysis
    • Sinonasal infection:
      • Acute localized pain (including pain radiating to the eye)
      • Nasal ulcer with black eschar
      • Extension from the paranasal sinus across bony barriers, including into the orbit
    • CNS infection: 1 of the following 2 signs
      • Focal lesions on imaging
      • Meningeal enhancement on MRI or CT
  • Mycological evidence
    • Direct test (cytology, direct microscopy, or culture)
      • Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate samples, indicated by 1 of the following:
      • Presence of fungal elements indicating a mold
      • Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or Scedosporium species)
    • Tracheobronchitis
      • Aspergillus on BAL or bronchial brush culture
      • Microscopy showing fungal elements on BAL or bronchial brush
    • Sinonasal disease
      • Mold on culture or microscopy of sinus aspirate
    • For Aspergillus
      • Galactomannan in plasma, serum, BAL, or CSF
        • Serum or plasma ≥1
        • BAL ≥1
        • Serum or plasma ≥0.7 and BAL ≥0.8
        • CSF ≥1
      • PCR
        • Plasma, serum, or whole blood positive on 2 consecutive tests
        • BAL positive on 2 or more tests
        • At least 1 positive from plasma, serum, or whole blood and one positive from BAL

Other Invasive Fungi

Candidiasis

  • Host factors
    • Recent history of neutropenia <0.5 × 109 neutrophils/L (<500 neutrophils/mm3 for >10 days) temporally related to the onset of invasive fungal disease
    • Hematologic malignancy
    • Receipt of an allogeneic stem cell transplant
    • Solid organ transplant recipient
    • Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a therapeutic dose of ≥0.3 mg/kg corticosteroids for ≥3 weeks in the past 60 days
    • Treatment with other recognized T-cell immunosuppressants, such as calcineurin inhibitors, tumor necrosis factor-a blockers, lymphocyte-specific monoclonal antibodies, immunosuppressive nucleoside analogues during the past 90 days
    • Inherited severe immunodeficiency (such as chronic granulomatous disease, STAT 3 deficiency, CARD9 deficiency, STAT-1 gain of function, or severe combined immunodeficiency)
    • Acute graft-versus-host disease grade III or IV involving the gut, lungs, or liver that is refractory to first-line treatment with steroids
  • Clinical features
    • At least 1 of the following 2 entities after an episode of candidemia within the previous 2 weeks:
      • Small, target-like abscesses in liver or spleen (bull’s-eye lesions) or in the brain, or, meningeal enhancement
      • Progressive retinal exudates or vitreal opacities on ophthalmologic examination
  • Mycological evidence
    • ß-D-glucan (Fungitell) ≥80 ng/L (pg/mL) detected in at least 2 consecutive serum samples provided that other etiologies have been excluded
    • Positive T2Candida

Cryptococcosis

  • Host factors
    • HIV infection
    • Solid organ or stem cell transplant recipient
    • Hematologic malignancy
    • Antibody deficiency (eg, common variable immunoglobulin deficiency)
    • Immunosuppressive therapy (including monoclonal antibodies)
    • End-stage liver or renal disease
    • Idiopathic CD4 lymphocytopenia
  • Clinical features
    • Meningeal inflammation
    • Radiological lesion consistent with cryptococcal disease
  • Mycological evidence
    • Recovery of Cryptococcus from a specimen obtained from any nonsterile site

Pneumocystosis

  • Host factors
    • Low CD4 lymphocyte counts <200 cells/mm3 (200 × 106 cells/L) for any reason
    • Exposure to medication (antineoplastic therapy, antiinflammatory, or immunosuppressive treatment) associated with T-cell dysfunction
    • Use of therapeutic doses of ≥0.3 mg/kg prednisone equivalent for ≥2 weeks in the past 60 days
    • Solid organ transplant
  • Clinical features
    • Any consistent radiographic features particularly bilateral ground glass opacities, consolidations, small nodules or unilateral infiltrates lobar infiltrate, nodular infiltrate with or without cavitation, multifocal infiltrates, miliary pattern
    • Respiratory symptoms with cough, dyspnea, and hypoxemia accompanying radiographic abnormalities including consolidations, small nodules, unilateral infiltrates, pleural effusions, or cystic lesions on chest X-ray or computed tomography scan
  • Mycological evidence
    • ß-D-glucan (Fungitell) ≥80 ng/L (pg/mL) detection in ≥2 consecutive serum samples provided other etiologies have been excluded
    • Detection of Pneumocystis jirovecii DNA by quantitative real-time polymerase chain reaction in a respiratory tract specimen

Endemic Mycoses

  • Host factors
    • Not applicable as these diseases affect both healthy and less healthy hosts
  • Clinical features
    • Evidence for geographical or occupational exposure (including remote) to the fungus and compatible clinical illness
  • Mycological evidence
    • Histoplasma or Blastomyces antigen in urine, serum, or body fluid
    • Antibody to Coccidioides in cerebrospinal fluid or 2-fold rise in 2 consecutive serum samples

Categories

Proven

Probable

  • Probable invasive fungal diseases requires at least one host factor, a clinical feature, and mycologic evidence
  • Only relevant for immunocompromised patients

Possible

  • Only cases with at least one host factor and at least one clinical evidence, but without supporting mycological evidence
  • Not used for endemic fungi

Further Reading

  • Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. doi: 10.1093/cid/ciz1008. PMID: 31802125; PMCID: PMC7486838.

References

  1. ^  Oliver A. Cornely, Johan Maertens, Drew J. Winston, John Perfect, Andrew J. Ullmann, Thomas J. Walsh, David Helfgott, Jerzy Holowiecki, Dick Stockelberg, Yeow-Tee Goh, Mario Petrini, Cathy Hardalo, Ramachandran Suresh, David Angulo-Gonzalez. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. New England Journal of Medicine. 2007;356(4):348-359. doi:10.1056/nejmoa061094.
  2. ^  Ben De Pauw, Thomas J. Walsh, J. Peter Donnelly, David A. Stevens, John E. Edwards, Thierry Calandra, Peter G. Pappas, Johan Maertens, Olivier Lortholary, Carol A. Kauffman, David W. Denning, Thomas F. Patterson, Georg Maschmeyer, Jacques Bille, William E. Dismukes, Raoul Herbrecht, William W. Hope, Christopher C. Kibbler, Bart Jan Kullberg, Kieren A. Marr, Patricia Muñoz, Frank C. Odds, John R. Perfect, Angela Restrepo, Markus Ruhnke, Brahm H. Segal, Jack D. Sobel, Tania C. Sorrell, Claudio Viscoli, John R. Wingard, Theoklis Zaoutis, John E. Bennett. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases. 2008;46(12):1813-1821. doi:10.1086/588660.

Retrieved from "https://idwiki.org/index.php?title=Invasive_fungal_infection&oldid=10422"
Powered by MediaWiki
Powered by Semantic MediaWiki